Study guide

11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple

CBCN Certified Breast Care Nurse Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CBCN Exam

CBCN Exam Facts, 2026 Blueprint & Study Plan

2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)

1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes

3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)

2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations

4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)

3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation

5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)

4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance

6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)

5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques

7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)

6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification

8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)

7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET

9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)

8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery

10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)

9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens

11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)

10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs

12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)

11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations

13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)

12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy

14 Chapter 13: Oncologic Emergencies (Nursing Practice)

13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism

15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)

14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use

16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)

15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health

11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple

Key Takeaways Explain This Topic AI

Inflammatory breast cancer is a clinical diagnosis of rapid-onset erythema, edema, and peau d'orange involving at least one third of the breast within 6 months, confirmed by biopsy of invasive carcinoma.

Inflammatory breast cancer is staged T4d and treated with trimodality therapy: neoadjuvant systemic therapy, modified radical mastectomy, and post-mastectomy radiation to the chest wall and regional nodes.

Sentinel lymph node biopsy, skin-sparing or nipple-sparing mastectomy, and immediate reconstruction are not used in inflammatory breast cancer.

Paget disease presents as unilateral scaling, crusting, or erosion that starts on the nipple, and most patients have an underlying DCIS or invasive cancer.

Paget disease is diagnosed with a full-thickness nipple biopsy plus diagnostic mammography and ultrasound, with MRI when imaging is negative.

Last updated: September 2026

  • Inflammatory Breast Cancer
  • Definition and Epidemiology

Inflammatory breast cancer (IBC) accounts for about 1% to 5% of breast cancers but a disproportionate share of deaths. It is more common in younger women, Black women, and women with obesity, and it is often HER2-positive or triple-negative. About one third of patients have distant metastases at diagnosis.

IBC is a clinical diagnosis confirmed by pathology. International consensus criteria require:

Rapid onset of breast erythema, edema, and/or peau d'orange, with or without a palpable mass.

Duration of 6 months or less .

Involvement of at least one third of the breast.

Pathologic confirmation of invasive carcinoma.

Tumor emboli in dermal lymphatics support the diagnosis but are not required , and finding them without the clinical picture does not make a tumor IBC. The AJCC category is T4d , so IBC is at least stage IIIB.

Mimics: When "Mastitis" Is Not Mastitis

The breast is red, warm, heavy, and swollen, often without a lump, so IBC is frequently misdiagnosed as mastitis or cellulitis. Red flags: a nonlactating woman, no fever or modest systemic symptoms, peau d'orange, rapid enlargement, nipple flattening, or no improvement after 7 to 14 days of antibiotics. Any presumed infection that does not resolve with one course of antibiotics needs imaging and biopsy.

Workup

Bilateral diagnostic mammography and ultrasound of the breast and regional nodes; breast MRI is often added.

Core biopsy of the breast mass or abnormal tissue, and a skin punch biopsy.

ER, PR, and HER2.

Systemic staging with contrast CT of chest, abdomen, and pelvis plus bone scan, or FDG PET/CT.

Genetic counseling and fertility discussion.

Trimodality Treatment

Neoadjuvant systemic therapy: anthracycline- and taxane-based chemotherapy, with trastuzumab and pertuzumab for HER2-positive disease; pathway-specific agents follow tumor biology.

Modified radical mastectomy: total mastectomy with level I and II axillary dissection. Sentinel node biopsy is not reliable because dermal lymphatics are obstructed. Skin-sparing and nipple-sparing mastectomy are not used because the skin is involved. Reconstruction is usually delayed until after radiation.

Post-mastectomy radiation to the chest wall and regional nodes, including supraclavicular and internal mammary nodes as indicated.

Adjuvant therapy by subtype: endocrine therapy, completion of HER2 therapy, or capecitabine or other escalation for residual disease.

Breast-conserving surgery is contraindicated. Even with aggressive therapy, long-term survival is lower than for other stage III cancers, so psychosocial support and clear communication matter.

Nursing Priorities in IBC

Expedite referral: IBC can progress over weeks.

Photograph and measure erythema to track response.

Prepare patients for an intense, lengthy plan and for mastectomy without immediate reconstruction.

Monitor lymphedema risk after axillary dissection and nodal radiation.

Connect patients with IBC-specific support resources.

  • Paget Disease of the Nipple
  • Presentation

Paget disease accounts for about 1% to 4% of breast cancers. Malignant Paget cells infiltrate the epidermis of the nipple, causing:

Unilateral scaling, crusting, redness, oozing, or erosion that begins on the nipple and may spread to the areola.

Itching, burning, or bleeding.

In advanced cases, nipple destruction.

Most patients (well over 80% in most series) have an underlying DCIS or invasive carcinoma , which may be palpable or visible on imaging, or may be found only with MRI.

Paget Disease Versus Eczema

  • Feature Paget disease Nipple eczema
  • Laterality Usually one side Often both sides
  • Starting point Nipple first, spreading to areola Areola or surrounding skin, often sparing the nipple
  • Response to steroid cream Temporary or none Improves within about 2 weeks
  • Associated findings Possible mass or discharge History of atopic dermatitis

Any unilateral nipple rash that does not resolve after a short trial of topical steroids needs biopsy.

Workup and Treatment

Full-thickness wedge or punch biopsy of the nipple skin; Paget cells are usually CK7-positive and often HER2-positive.

Bilateral diagnostic mammography and ultrasound; breast MRI when these are negative, to find an occult underlying cancer.

Surgery: central lumpectomy removing the nipple-areolar complex followed by whole-breast radiation is appropriate when disease is limited to the central breast and margins can be cleared. Mastectomy is chosen for extensive or multicentric disease.

Axillary staging: sentinel node biopsy when invasive cancer is present or when mastectomy is performed.

Paget disease without underlying cancer is staged Tis (Paget) ; otherwise the underlying tumor determines stage.

Adjuvant therapy follows the underlying tumor's biology.

Nursing Priorities in Paget Disease

Validate that a delayed diagnosis after months of "eczema" treatment is common and frustrating. Discuss nipple loss and later nipple reconstruction or 3D tattooing, and teach wound care after central lumpectomy.

Primary Inflammatory Cancer Versus Neglected Locally Advanced Cancer

Not every red, swollen breast with cancer is inflammatory breast cancer. A long-standing, neglected locally advanced tumor can ulcerate or cause secondary skin redness and edema over the mass (usually classified T4b). Primary IBC is defined by its rapid onset within 6 months and diffuse involvement, often without a dominant mass. The distinction matters because IBC carries a worse prognosis and requires trimodality therapy and full staging.

Survivorship After IBC

Survivors of IBC face a higher risk of recurrence than other stage III survivors, and many have had axillary dissection and nodal radiation, so lymphedema surveillance is essential. Body image concerns are common because reconstruction is delayed and the chest wall receives high-dose radiation. Surveillance follows standard schedules without routine scans, and clinical trials are encouraged at every stage.